Should You Buy Lexicon Pharmaceuticals Stock?
Investing in biotech stocks is a risky endeavor, but sometimes you can eke out a return without facing as much potential trouble as usual. By identifying companies that are likely to report rapid revenue growth in the next few years, you'll be most of the way toward profit.
Of course, that's easier said than done -- except in the case of Lexicon Pharmaceuticals (NASDAQ: LXRX). Right now, Lexicon is putting the finishing touches on a few of its longest-incubating projects and awaiting the final go-ahead from regulators. If all goes well, it'll soon be a self-sustaining competitor in the diabetes space. Investors take note: This kind of opportunity won't knock twice.
Image source: Getty Images.
Source Fool.com
